

Alma Mater Studiorum Università di Bologna Archivio istituzionale della ricerca

Canine smooth muscle tumors: A clinicopathological study

This is the final peer-reviewed author's accepted manuscript (postprint) of the following publication:

Published Version: Canine smooth muscle tumors: A clinicopathological study / Avallone G.; Pellegrino V.; Muscatello L.V.; Roccabianca P.; Castellani G.; Sala C.; Tecilla M.; Valenti P.; Sarli G. - In: VETERINARY PATHOLOGY. - ISSN 0300-9858. - STAMPA. - 59:2(2021), pp. 244-255. [10.1177/03009858211066862]

Availability: This version is available at: https://hdl.handle.net/11585/849067 since: 2023-04-05

Published:

DOI: http://doi.org/10.1177/03009858211066862

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (https://cris.unibo.it/). When citing, please refer to the published version.

(Article begins on next page)

This is the peer-reviewed accepted manuscript of:

Avallone G, Pellegrino V, Muscatello LV, Roccabianca P, Castellani G, Sala C, Tecilla M, Valenti P, Sarli G.

Canine smooth muscle tumors: A clinicopathological study.

Vet Pathol. 2022 Mar;59(2):244-25

The final published version is available online at:

https://doi.org/10.1177/03009858211066862

Terms of use:

Some rights reserved. The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. For all terms of use and more information see the publisher's website.

This item was downloaded from IRIS Università di Bologna (<u>https://cris.unibo.it/</u>)

When citing, please refer to the published version.

- 8 Canine smooth muscle tumors: a clinicopathological study
- 9 Giancarlo Avallone, Valeria Pellegrino, Luisa Vera Muscatello, Paola Roccabianca,
- 10 Gastone Castellani, Claudia Sala, Marco Tecilla, Paola Valenti, Giuseppe Sarli.
- 11 Department of Veterinary Medical Sciences (DIMEVET), University di Bologna, Ozzano
- 12 dell'Emilia (BO), Italy (GA, VP, LVM, GS).
- 13 Department of Veterinary Medicine (DIMEVET), University of Milano, Lodi (LO), Italy (MT,
- 14 PR).
- 15 Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna
- 16 (GC).
- 17 Department of Physics and Astronomy, University of Bologna (CS).
- 18 Clinica Veterinaria Malpensa, Samarate (VA), Italy (PV).
- 19
- 20
- 21 Corresponding Author:
- 22 Giancarlo Avallone
- 23 e-mail: giancarlo.avallone@unibo.it
- 24 Tel: +39 051302965
- 25 Address: Department of Veterinary Medical Sciences (DIMEVET), University of Bologna,
- 26 Via Tolara di Sopra 50, 40064 Ozzano dell'Emilia (BO), Italy.

27 Abstract

28 Canine smooth muscle tumors (SMTs) commonly develop in the alimentary and female 29 genital tracts, and less frequently in soft tissue. The definition of histological criteria of 30 malignancy is less detailed for SMTs in dogs than in humans. This study evaluated the 31 clinicopathologic features of canine SMTs and compared the veterinary and human 32 medical criteria of malignancy. A total of 105 canine SMTs were evaluated histologically 33 and classified according to both veterinary and human criteria. The Ki67 labeling index 34 was assessed in all SMTs. Estrogen (ER) and progesterone (PR) receptor expression was 35 evaluated for soft tissue SMTs. Follow-up data were available in 25 cases. SMTs were 36 diagnosed in the female genital tract (42%), alimentary tract (22%), and soft tissue (20%). 37 Soft tissue SMTs frequently arose in the peri-genital area, pelvic cavity, and 38 retroperitoneum. A subset of soft tissue SMTs expressed ER and/or PR, resembling 39 gynecologic type of soft tissue SMT in humans. SMTs were less frequently malignant 40 when assessed with human criteria than with veterinary criteria, better reflecting their 41 benign behavior, especially in the genital tract where human criteria tolerate a higher 42 mitotic count for leiomyoma. Decreased differentiation correlated with increased 43 proliferation, necrosis and reduced desmin expression. Mitotic count, Ki67-labeling index, 44 and necrosis correlated with metastases and tumor-related death. Further prognostic 45 studies are warranted to confirm the better performance of the human criteria when 46 assessing SMT malignancy, especially genital cases, to confirm their usefulness in 47 ER/PR-expressing soft tissue SMTs, and to better define the most useful prognostic 48 parameters for canine SMTs.

49

Keywords: desmin, dogs, hormone receptors, leiomyoma, leiomyosarcoma, grading,
prognosis, smooth muscle tumors, soft tissue, soft tissue sarcoma.

52

53 Canine smooth muscle tumors (SMTs) arise more often in the female genital and 54 alimentary tracts, and less commonly in the lower urinary tract, soft tissue, and spleen.² In 55 the alimentary tract, SMTs arise more frequently in the stomach, where they are mostly 56 benign, and in the intestine, where they are more often malignant, while esophageal SMTs 57 are less common.² Most information about canine alimentary SMTs precedes the first 58 descriptions of canine gastrointestinal stromal tumors (GISTs).² This may have distorted 59 the data in earlier reports as GISTs and SMTs often require differentiation by 60 immunohistochemistry.

61 SMTs of the female genital tract are largely benign and often express estrogen receptors

62 (ER) and progesterone receptors (PR).^{2,14} SMTs of the lower urinary tract are less

63 common but still represent the majority of urinary bladder mesenchymal tumors.² Splenic

SMTs have been grouped among stromal tumors, but specific studies regarding their
 prognosis and behavior in dogs are lacking.¹⁰

Canine cutaneous and subcutaneous SMTs are reported to have a good prognosis,¹² but
 information is mostly restricted to tumors derived from the arrector pili muscles or from
 vessel walls.^{12,18} On the contrary, studies on deep-seated canine soft tissue SMTs are

69 lacking. Furthermore, despite the knowledge available for human SMTs,^{6,7} hormone

70 receptor expression in canine soft tissue SMTs is largely unknown.

71 In dogs, the distinction between benign and malignant SMTs relies mainly on the

morphological assessment of necrosis, infiltrative growth, and mitotic activity. However,

73 current veterinary guidelines do not provide specific cut-off levels for these parameters and

do not take into consideration the primary site of the tumor.² In contrast, specific guidelines

are available for the morphological assessment of SMTs in humans.^{13,19} In humans,

76 morphologic criteria for a diagnosis of leiomyosarcoma, rather than leiomyoma, include

77 mitotic count, nuclear atypia, and tumor cell necrosis.^{13,19} The cut-offs for mitotic count

vary according to tumor site: while any proliferative activity is considered an indication of

79	malignancy in most sites, up to 9 mitoses in 10 high power fields (HPFs) are tolerated in
80	female genital tract SMTs, as these tumors are often considered to be benign. ¹³
81	Due to the paucity of up-to-date information regarding canine SMTs, the aims of this study
82	were to:
83	• Describe the organ distribution and the clinicopathologic features of canine SMTs.
84	• Provide a detailed pathologic evaluation of canine soft tissue SMTs, including deep-
85	seated tumors and expression of hormone receptors.
86	Compare the performance of the morphological criteria of malignancy used in
87	veterinary medicine (veterinary criteria) with those used in human medicine (human
88	criteria) to separate benign and malignant SMTs in dogs.
89	
90	Materials and methods
91	Case selection and clinical information
92	Cases from 2001-2017 of canine spindle cell neoplasms with a histological diagnosis
93	(definitive or presumptive) of SMT, or for which a possible smooth muscle origin was
94	hypothesized, were retrospectively collected from the archives of two different institutions.
95	Cases morphologically consistent with a smooth muscle cell origin, ¹⁸ negative for CD117
96	(which excludes GISTs), and expressing α -SMA and/or desmin were included in this study
97	as canine SMTs.
98	Data were collected regarding the breed, age, sex, and neutering status of each dog, as
99	well as the site of development, and size of each neoplasm. The size was defined as the
100	largest tumor diameter measured at the trimming station after fixation. Tumors of the
101	female genital tract, alimentary tract, soft tissue, lower urinary tract, spleen, and
102	miscellaneous SMTs were included in this study.
103	Diagnosis

104	Hematoxylin and eosin (H&E)-stained sections from each case were re-evaluated at a
105	multi-head microscope by two pathologists (GA and VP). The following histological
106	features were assessed according to their description in the human criteria: 13, 19
107	 differentiation, classified as well-differentiated (similar to normal tissue),
108	intermediate differentiation (histologic type can be determined), or poorly
109	differentiated (undifferentiated tumors);
110	 nuclear atypia, classified as absent, mild, moderate, or severe;
111	• necrosis, classified as absent, < 50% of the tumor, or \ge 50% of the tumor
112	(microscopically assessing all available sections);
113	 nuclear shape, classified as oval, cigar-shaped, or slender (long, often
114	hyperchromatic and occasionally twisted). Classification was based on the nuclear
115	morphology of the majority of neoplastic cells;
116	• prominent vascularization, perivascular fibrosis, hyalinized stroma, trabecular
117	pattern (neoplastic smooth muscle cells arranged in anastomosing trabeculae
118	separated by extracellular matrix), myxoid differentiation (presence of myxoid
119	matrix), mineralization, vesicular chromatin, nuclear palisading (nuclei lined up and
120	alternating with anuclear zones), and multinucleation (all classified as present or
121	absent).
122	The diagnosis of leiomyoma or leiomyosarcoma was based on both the veterinary criteria ²
123	and the human criteria. ^{13,19} Leiomyosarcoma was diagnosed, independent of the site of
124	occurrence, when at least one of the following veterinary criteria indicative of malignancy
125	was observed (cases with none of these features were diagnosed as leiomyoma):
126	• mitotic count of at least 1 mitotic figure in 10 high-power fields equivalent to the
127	standard area of 2.37 mm²;
128	 infiltration into adjacent tissues;
129	presence of necrosis.

130 The human criteria¹³ indicative of malignancy for SMTs not located in the female genital

131 tract included at least one of the following:

• any mitotic figures within neoplastic cells;

nuclear atypia (defined as more than mild, clearly visible with a 10x objective lens,
 and including abnormal shape, karyomegaly, and prominent nucleoli). Rare,

scattered, large hyperchromatic nuclei with intranuclear cytoplasmic inclusions were
not considered as nuclear atypia, but represented a degenerative change (so-called
ancient change);

• tumor cell necrosis. Infarct-type necrosis was not considered to be a criterion for

139 malignancy, and was differentiated from tumor cell necrosis by the presence of the

following features: central location; abrupt transition with viable neoplastic cells;

141 presence of either granulation tissue or hyalinized stroma between the necrotic and

142 non-necrotic areas; recent hemorrhage; mummified appearance showing outlines of

143 the tumor cells; and both tumor and vessels appearing necrotic. In contrast, tumor

144 cell necrosis had a scalloped outline and the neoplastic cells surrounding vessels

145 were usually spared.

The human criteria^{13,19} provide the following specific diagnostic algorithm for SMTs located
in the female genital tract:

concurrent nuclear atypia (more than mild, visible with a 10x objective lens) and
 tumor cell necrosis (as previously described, and independent of mitotic activity)
 indicates leiomyosarcoma;

• presence of either nuclear atypia or tumor cell necrosis, combined with a mitotic 152 count \geq 10 in 10 HPF (while not specified in the original studies,^{13,19} in the present 153 study a standard area of 2.37 mm² was evaluated) indicates leiomyosarcoma;

a mitotic count ≤ 9 in 10 HPF (2.37 mm²) when both nuclear atypia and necrosis are
 absent indicates leiomyoma;

a diagnosis of SMT with unknown malignant potential (SMT-UMP) is recommended
 in all other genital cases.

158 Histochemical evaluation

Masson's trichrome stain was performed with a commercially available kit (Code: 04-010802, Bio-Optica, Milano, IT) in all cases to assess the amount and distribution of collagen within the canine SMTs. The amount of collagen was scored as absent, scant, moderate, or abundant. The collagen distribution pattern was classified as interfascicular (when separating bundles of neoplastic cells), interstitial (when surrounding single neoplastic cells), or mixed (a combination of the previous two).

165 Immunohistochemistry

166 Immunohistochemistry for α -smooth muscle actin (α -SMA), desmin, and CD117 was

167 performed on tissue microarrays using a previously validated protocol.¹⁷ Any further

staining (histochemical and immunohistochemical) for Ki67 and hormonal receptors was

169 performed on full sections of selected cases. Immunohistochemistry for α -smooth muscle

170~ actin ($\alpha\text{-SMA}$), desmin, CD117 and Ki67 was performed in all cases while ER and PR

171 expression was assessed only in soft tissue SMTs.

172 Three micrometer thick sections were dewaxed and rehydrated. Endogenous peroxidase

173 was blocked by immersion in 3% H₂O₂ in methanol for 30 minutes. Source, dilution, and

174 retrieval protocols for each antibody are reported in Supplementary Table S1.

175 The reaction was amplified by the avidin-biotin method (Vectastain® Elite ABC-HRP kit,

176 Vector, Burlingame, CA, USA) and visualized with 0.04% 3,3'-diaminobenzidine (Code: 10-

177 0048, Histoline Milano, IT) for 4 minutes. Sections were counterstained with hematoxylin,

178 rinsed in tap water and dehydrated, before a coverslip was added. The following positive

179 controls were used: sections of canine small intestine for α -SMA, desmin, and Ki67

180 staining; sections of a canine GIST for CD117 staining; and sections of canine uterus for

181 ER and PR expression. Negative controls comprised slides incubated with omission of the

182 primary antibody and normal tissues known to be non-reactive for the specific antibody.

183 Ki67 expression was evaluated as the labeling index and defined as the percentage of

184 Ki67-positive cells. Ki67-positive cells were counted in 10 HPF (400x) counting at least

185 1000 cells for each case, using the manual count tool of the ImageJ 1.48 analysis

186 software.

187 Follow-up

188 Collection of follow-up data was attempted for all cases by phone calls with referring

189 veterinarians. Follow-up data included: tumor recurrence; metastasis; and tumor-related

190 death.

191 Statistical analysis

192 Correlations between histologic variables were obtained with the Spearman test. A p-value

 $193 \leq 0.05$ was considered significant. The normality of data distribution was assessed

according to the D'Agostino and Pearson omnibus test. Statistical analysis was performed

using GraphPad Prism 8.3 (GraphPad Software, Inc.).

196 Furthermore, three statistical models were used to determine the association of each

197 variable with the diagnosis (with and without confounding variables) and to identify a

198 multivariable predictive model for the diagnosis.

199 Univariate logistic regression models were fitted for each variable to test its association

with the diagnosis (according to both the veterinary and human criteria). The Wald's test

and the Likelihood Ratio Test were used to assess statistical significance. Each model was

202 evaluated by adjusting the variables for confounding effects (age, tissue, and sex) and with

203 no adjustment. P-values were adjusted for multiple testing using the BH procedure.

204 Results were sorted according to the residual deviance. A smaller residual deviance

205 means that the variable better predicts the diagnosis.

A multivariable model was obtained by elastic net regression. The penalization parameter

207 was evaluated using the cross-validation procedure of the cv.glment function from the

glmnet library in R (accessed June 2014). A Leave-One-Out (LOO) cross-validation was
used to test the prediction accuracy and the AUC of ROC was thus calculated. The
importance of each variable in the model was estimated as the average of the coefficients
obtained in each LOO iteration and standard deviations were also reported. For the
diagnosis according to the human criteria, the model was computed three times,
considering only one pair of outcomes at a time. All analyses were performed in R 3.6.3.
Missing values were imputed with the mice algorithm v3.5.0 in R.¹

215 Microscopic images depicting the histological features assessed are available as

216 Supplemental material.

217 **Results**

218 Selection criteria were met for 105 canine SMTs from 104 dogs. A total of 71/104 dogs 219 were female (69%, 14 of which were spayed) and 32/104 dogs were male (31%, 9 of 220 which were castrated). In one case, the sex was unknown. Table 1 lists the sex distribution 221 parsed by the primary site of the neoplasm. Most dogs were crossbreed 41/104, followed 222 by retrievers 12/104 and boxers 6/104. Sixteen other breeds were represented, with one to 223 three cases each. The median age of the total cohort was 11 years (range 3-17), the 224 median age of dogs with splenic SMTs was 11.2 years, and the median age was 11 years 225 in all other groups. The age range was 3-15 years for dogs with tumors of the genital tract, 226 4-17 years for dogs with alimentary tumors, 4-15 years for dogs with soft tissue tumors, 6-227 13 years for dogs with lower urinary tract tumors, and 10-12 years for dogs with splenic 228 tumors. No statistically significant differences were found in the age of dogs based on sex 229 or tumor site. SMTs of the female genital tract developed in younger dogs, with a peak 230 incidence at 8-9 years of age (Fig. 1). Forty-four tumors were in the female genital tract, 23 231 in the alimentary system, 21 in soft tissue, 11 in the lower urinary tract, 4 in the spleen and 232 2 in other sites (Fig. 2). Tumor size ranged between 0.5 cm and 15 cm (median = 3.2 cm; 233 mean = 4.6 cm).

234 Histologic and immunohistochemical features

Histologic features are listed in Table 2 and illustrated in Figures 3-17. All cases expressed α -SMA diffusely and 73/105 cases (70%) expressed desmin either diffusely or multifocally (Fig. 18-21). Estrogen and/or progesterone receptors were expressed in 7/21 soft tissue SMTs (Fig. 22-23).

239 Several statistically significant correlations were identified with the Spearman test (p- and 240 R-values are listed in Supplemental Table S2). Reduced differentiation was correlated with 241 increased tumor size, higher proliferative activity (both mitotic count and Ki67 labeling 242 index), increased amount of tumor cell necrosis, presence of multinucleation, and lack of 243 desmin expression (Fig. 24-27). Greater amount of tumor cell necrosis correlated with 244 increased size, higher mitotic count, greater collagen amount, and interstitial or mixed 245 collagen pattern. Higher mitotic count correlated with higher Ki67 labeling index, lack of 246 desmin expression and presence of multinucleation. Presence of nuclear atypia correlated 247 with increased proliferative activity (both mitotic count and Ki67 labeling index) and 248 presence of multinucleation. The finding of hyalinized areas correlated with trabecular 249 pattern, multinucleated cells, and myxoid areas. The amount of collagen was correlated 250 with its distribution pattern, being more abundant in cases with interstitial and mixed 251 distribution.

252 Diagnoses according to the veterinary and human criteria for SMT malignancy

According to the veterinary criteria, 22/105 cases were diagnosed as leiomyoma and 83/105 were diagnosed as leiomyosarcoma. According to the human criteria, 42/105 cases were identified as leiomyoma, 11/105 cases as SMT-UMP and 52/105 cases as leiomyosarcoma. There was disagreement in the veterinary and human definition of malignancy in 31 SMT cases, which were all classified as malignant according to the veterinary criteria, but were diagnosed as leiomyoma (20 cases) or SMT-UMP (11 cases) using the human criteria. Twenty-six of the 31 discordant cases were in the female genital
tract, 3/31 were in the alimentary tract, 1/31 was in soft tissue and 1/31 was in the kidney.
Re-classification according to the human criteria was based on the following:

• Ten cases were diagnosed as leiomyosarcoma based on the veterinary criteria because of the presence of necrosis. These cases were re-classified as leiomyoma based on the human criteria because the necrosis was of the infarct-type and concurrent atypia and mitotic activity were absent. Five of these cases were genital and five were extragenital.

• Ten cases were diagnosed as leiomyosarcoma based on the veterinary criteria because of the presence of mitotic activity. These cases were re-classified as leiomyoma based on the human criteria because the mitotic count was below 10 and the tumors arose in the female genital tract.

Ten cases were diagnosed as leiomyosarcoma based on the veterinary criteria
 because of the concurrent presence of mitotic activity and tumor cell necrosis.
 These cases were re-classified as SMT-UMP according to the human criteria
 because the mitotic count was below 10 and the tumors developed in the female
 qenital tract.

• One case was diagnosed as leiomyosarcoma based on the veterinary criteria

277 because of the presence of mitotic activity. This case was re-classified as SMT-

UMP based on the human criteria because, despite a mitotic count of 13, atypia and

tumor cell necrosis were absent, and the tumor was in the female genital tract.

280 Clinicopathologic features of canine SMTs in distinct anatomical sites

There were 44 genital tract SMTs, of which 30 were vaginal, 11 uterine, and 3 vulvar. The

veterinary criteria identified 12 leiomyomas and 32 leiomyosarcomas, while the human

criteria identified 27 leiomyomas, 11 SMTs-UMP, and 6 leiomyosarcomas.

284 There were 23 alimentary SMTs, of which 1 was in the esophagus, 8 were in the stomach, 285 11 were in the small intestine, and 3 were in the large intestine. The veterinary criteria 286 identified 4 leiomyomas and 19 leiomyosarcomas, while the human criteria identified 7 287 leiomyomas and 16 leiomyosarcomas. 288 There were 21 SMTs located in the soft tissue, of which 10 were superficial 289 (subcutaneous) and 11 were deep-seated (below the subcutis or intracavitary). Superficial 290 cases were located on the limbs (5 cases), perineal region (3 cases), or perianal region (2 291 cases). Deep-seated cases were retroperitoneal (5 cases), intrapelvic (4 cases), 292 mesenteric (1 case), or within the muscles of the pelvic diaphragm (1 case). The veterinary 293 criteria identified 2 leiomyomas and 19 leiomyosarcomas, while the human criteria 294 identified 3 leiomyomas and 18 leiomyosarcomas. Of the 21 soft tissue SMTs, 7 295 expressed hormone receptors (6 leiomyosarcomas and 1 leiomyoma, according with both 296 veterinary and human criteria); 5 of these were ER-positive and PR-negative, 1 was PR-297 positive and ER-negative, and 1 was ER- and PR-positive (Fig. 22-23). Three of the 298 hormone receptors-expressing soft tissue SMTs were deep-seated (2 retroperitoneal and 299 1 intrapelvic) and 4 were subcutaneous (all in the perianal or perineal region). 300 There were 11 SMTs of the urinary bladder. The veterinary and human criteria were 301 concordant in these cases and both sets of criteria identified 4 leiomyomas and 7 302 leiomyosarcomas. There were 4 splenic SMTs, all diagnosed as leiomyosarcomas with 303 both the veterinary and human criteria. Other sites (miscellaneous) included 1 kidney and 304 1 gallbladder SMT, and these were diagnosed as leiomyoma and leiomyosarcoma 305 respectively with both the veterinary and human criteria.

306 Clinical follow-up

Clinical follow-up data were available for 25 cases. Overall, 4/25 dogs had evidence of
 local recurrence or metastasis. Specifically, 1 dog with soft tissue (pelvic diaphragm) SMT
 developed local recurrence; 2 dogs (one with perineal SMT and one with small intestinal

310 SMT) developed suspected metastases; and 1 dog with genital SMT developed both local 311 recurrence and suspected metastases. Metastases were confirmed in the liver by 312 histopathology in 1 dog and by diagnostic imaging (suspected metastases) in the brain of 313 1 dog and in the liver of another dog. Six dogs died due to tumor-related causes: 4 due to 314 relapse (recurrence, metastasis/or suspected metastasis, or both) and 2 were euthanized 315 during surgery for resection of an alimentary tract SMT. The status of surgical margins was 316 unknown in one of the two cases of recurrence (located in the soft tissue) and infiltrated in 317 the second case (located in the female genital tract).

The presence of metastases or suspected metastases correlated with mitotic count, tumor cell necrosis, Ki67 labeling index, and tumor-related death. Tumor-related deaths were correlated with the size, atypia, mitotic count, tumor cell necrosis, presence of nuclear atypia, Ki67 labeling index, differentiation, and lack of desmin expression. Recurrence was associated with perivascular fibrosis, palisading, multinucleated cells, and tumor-related death.

324 Of the 25 cases with available follow-up:

4 were diagnosed as leiomyoma by both the human criteria and the veterinary
 criteria, none of these developed relapses or died of tumor-related causes during
 the follow-up period.

6 were diagnosed as leiomyosarcoma with the veterinary criteria and as leiomyoma
 or SMT-UMP with the human criteria; none of these developed relapses or died of
 tumor-related causes during the follow-up period.

- 15 were diagnosed as leiomyosarcoma with both the veterinary and human criteria;
 all the cases which developed relapses/suspected relapses or died of tumor-related
 causes belong to this group.

There was no statically significant correlation between diagnosis and relapse or death fromtumor-related causes.

Association between the clinical and pathological variables and diagnoses.

After adjusting for confounding effects, univariate analysis showed that four variables were significantly associated with diagnosis according to the veterinary criteria: mitotic count; necrosis; Ki67 labeling index; and differentiation (Supplemental Table S3). The variables that were significantly associated with diagnosis according to the human criteria were: mitotic count; tumor cell necrosis; Ki67 labeling index; differentiation; nuclear atypia; and presence of multinucleated cells (Supplemental Table S4).

343 The elastic net model (multivariable model) identified a set of variables whose combination 344 was associated, with good accuracy, with the diagnosis according to the veterinary criteria 345 (AUC of ROC = 0.78 when considering 4 categories for sex; AUC of ROC = 0.811 when 346 considering 2 categories for sex) (Supplemental Table S5). Specifically, the variables that 347 showed a partial association with a diagnosis of leiomyosarcoma were a higher amount of 348 necrosis, increased mitotic count, presence of nuclear atypia, increased Ki67 labeling 349 index, soft tissue origin, sex (female intact, male intact and male castrated; or male when 350 considering 2 categories for sex), mixed collagen pattern, and poor differentiation. The 351 variables associated with a diagnosis of leiomyoma were presence of perivascular fibrosis, 352 desmin expression, vesicular chromatin, lower urinary tract origin, and increased collagen 353 amount. Results obtained considering either 4 or 2 categories for sex were consistent with 354 those listed above, but two other variables showed association with the diagnosis of 355 leiomyosarcoma when considering 2 categories for sex: the presence of hyalinized stroma 356 and slender nuclei.

When considering the diagnosis according to the human criteria, the prediction accuracy of the elastic-net model ranged from 0.688 (when discriminating between leiomyoma and SMT-UMP, and considering 2 categories for sex) to 0.974 (when discriminating between SMT-UMP and leiomyosarcoma, and considering 2 categories for sex), indicating good performance in all comparisons (Supplemental Tables S6, S7 and S8). 362 When comparing leiomyoma and leiomyosarcoma, the variables associated with a 363 diagnosis of leiomyosarcoma were: presence of nuclear atypia; increased mitotic count; 364 poor differentiation; soft tissue or splenic origin; increased Ki67 labeling index; sex (male 365 and male castrated, or male, when considering 2 categories for sex); mixed collagen 366 pattern; increased amount of tumor cell necrosis; oval nucleus; and perivascular fibrosis. 367 The variables associated with a diagnosis of leiomyoma were: genital origin; sex (female 368 intact); slender nucleus; absence of collagen; and myxoid differentiation. Results obtained 369 considering 4 or 2 categories of sex were consistent with those above, and when 370 considering 2 categories for sex, we also identified interfascicular collagen pattern to have 371 a weak association with a diagnosis of leiomyoma.

372 When comparing leiomyoma and SMT-UMP, the variables associated with a diagnosis of 373 SMT-UMP were: increased amount of tumor cell necrosis; increased mitotic count; female 374 genital tract origin; presence of trabecular pattern; loss of differentiation; presence of 375 nuclear palisading; and oval nucleus. The variables associated with the diagnosis of 376 leiomyoma were: cigar-shaped nucleus and alimentary tract origin. Results obtained 377 considering 4 or 2 categories of sex were consistent with those above, and when 378 considering 2 categories of sex, oval nucleus, mixed collagen pattern, and collagen 379 amount were also associated with a diagnosis of SMT-UMP, while hyalinized stroma was 380 associated with a diagnosis of leiomyoma.

Finally, when comparing SMT-UMP and leiomyosarcoma, the variables associated with a diagnosis of SMT-UMP were: female genital tract origin; presence of nuclear palisading; presence of trabecular pattern; slender and oval nucleus; interfascicular collagen pattern; sex (female intact); increased amount of collagen; tumor cell necrosis; and age. The variables associated with a diagnosis of leiomyosarcoma were: reduced desmin expression; increased mitotic count; increased nuclear atypia; increased Ki67 labeling index; presence of perivascular fibrosis; soft tissue origin; splenic and lower urinary tract 388 origin; reduced differentiation; vesicular chromatin; sex (male intact or male when

389 considering 2 categories for sex); hyalinized stroma; cigar-shaped nucleus; presence of

390 multinucleated cells; and mixed collagen pattern. The results obtained considering 4 or 2

391 categories of sex were consistent.

Raw data for each of the cases included are reported in supplemental table S9. Examples
of histological features not reported in figures 3 to 14 are reported in supplemental figures
S10.

395 **Discussion**

396 One of the main difficulties in the diagnosis and prognosis of SMTs in veterinary medicine

397 is the lack of specific guidelines to differentiate leiomyomas from leiomyosarcomas by

398 histopathology. Based on this premise, we applied and compared the histopathological

399 features used in veterinary and human medicine to a series of 105 canine SMTs to assess

400 the best morphological features that distinguish between benign and malignant

401 tumors.^{2,13,15,19} The statistically significant correlation between differentiation, proliferative

402 activity and tumor cell necrosis was expected, because these parameters are often

403 included in grading systems as indicators of malignancy.^{3,15}

404 Interestingly, when nuclear atypia was defined as more than mild and visible at 10x, it

405 correlated with differentiation, mitotic count, Ki67 labeling index and multinucleation. This

406 result was unexpected as the assessment of atypia has been reported to be subjective.

407 Our findings suggest that the guidelines used in human medicine¹³ allow for a more

408 reliable identification of nuclear atypia and avoid overestimation of this feature.

409 Importantly, nuclear atypia is a relevant feature of malignancy in human SMTs,¹³ and the

410 application of the same criterion to canine SMTs represents a promising method to

411 facilitate the distinction between benign and malignant SMTs.

412 Tumor cell necrosis was found to correlate with differentiation and proliferative activity, as

413 well as with the size of the tumor and amount of collagen. These correlations suggested

414 that angiogenesis may not always be efficient in SMTs and that hypoxia may develop,

415 leading to necrosis in larger tumors.

416 Another interesting finding was the correlation of mitotic count with reduced differentiation 417 and with a lack of desmin expression, suggesting that the loss of differentiated smooth 418 muscle cell markers may parallel an increase in proliferative potential. Finally, the amount 419 of collagen identified in canine SMTs was variable and correlated with the pattern of 420 collagen distribution, being more abundant in cases with interstitial and mixed collagen. 421 The amount of collagen also correlated with the amount of tumor cell necrosis. These 422 findings, and the lack of correlation with desmin expression or degree of differentiation, 423 suggest that the presence of collagen, even when surrounding individualized neoplastic 424 cells, does not imply a reduced differentiation of the tumor, but may more likely represent a 425 reaction to hypoxia.

426 Common histologic features of canine SMTs included nuclear palisading and trabecular 427 pattern, and both were more frequent in genital SMTs than in SMTs of other sites. These 428 features may represent features typical of genital SMTs and should be kept in mind 429 especially to avoid a misdiagnosis of peripheral nerve sheath tumors based on the 430 presence of nuclear palisading.

431 The veterinary and human criteria systems to discriminate between benign and malignant 432 SMTs disagreed in 30% of the canine SMT cases. All of these were diagnosed as 433 leiomyosarcomas according to the veterinary criteria but were re-classified as leiomyomas 434 or SMTs-UMP when following the human criteria. Most of these discordant cases were in 435 the female genital tract where the veterinary criteria identified 73% of genital SMT cases 436 as leiomyosarcoma, while the human criteria identified only 14% of these cases as 437 malignant. This result was expected considering that there are human criteria specific for 438 this location. Furthermore, the human criteria tolerate a greater mitotic count for a 439 diagnosis of genital leiomyoma, and that was the main reason for re-classification in this

440 study.^{13,19} The human criteria seemed to better reflect the benign behavior of the majority 441 of genital SMTs in dogs,² while the veterinary criteria seem to overestimate the diagnosis 442 of leiomyosarcoma in this site. Unfortunately, in our case series, follow-up data were 443 available only for a minority of dogs with SMTs. However, in that subset of patients, all the 444 cases associated with local recurrence and/or distant metastasis or tumor-related death 445 were classified as leiomyosarcoma with both the human and veterinary criteria. Thus, 446 further prospective prognostic studies on canine SMTs of the female genital tract are 447 needed to confirm that the human criteria predict their biological behavior better than the 448 veterinary criteria.

449 The second most frequent reason for re-classification was the morphological type of 450 necrosis as the human criteria specifically excludes infarct-type necrosis from the 451 morphological criteria of malignancy.¹³ This distinction between infarct-type and tumor cell 452 necrosis allowed the re-classification of only five extra-genital SMTs that were diagnosed 453 as leiomyosarcoma based on necrosis only, when using the veterinary criteria. The 454 exclusion of infarct-type necrosis is based on the fact that leiomyomas can reach a large 455 size (up to 15 cm in this case series), leading to a hypoxic microenvironment causing 456 central necrosis despite the benign nature of the tumor. Nevertheless, early small foci of 457 infarct-type necrosis might be difficult to differentiate from tumor-cell necrosis. Sections 458 should be carefully examined to identify specific morphological features to facilitate this 459 distinction.

Furthermore, the human criteria include a third category of SMT-UMP in the female genital tract: this category had a Ki67 labeling index lower than leiomyosarcomas (similar to leiomyomas) but a size larger than leiomyomas. Thus, SMTs-UMP may also have intermediate features between benign and malignant SMTs in dogs. Interestingly, all the cases with available follow-up data that were reclassified from leiomyosarcoma to a more benign category (leiomyoma or SMT-UMP) had benign tumor behavior. Since data regarding the behavior of neoplasms with intermediate histologic features of malignancy
are still scarce in human medicine¹⁹ and have never been investigated in dogs, this topic
warrants further evaluation.

The most frequent sites of SMT development in our caseload were the female genital and gastrointestinal tracts, paralleling previous reports.^{2,9,14} The third most-represented site was soft tissue, which was unexpected considering the paucity of reports on soft tissue SMTs in dogs.¹² The spleen was less represented than expected, but the number of splenic cases in this study may underestimate the true incidence of splenic SMTs since most SMTs in this study were collected from referral practices while splenectomy is often performed in general practice.

The distribution of SMTs within the different organ systems was expected. We found vaginal tumors to be the most frequent, as previously reported in the literature.² In the gastrointestinal tract, the small intestine was the most common site, followed by the stomach, while cases in the large intestine and esophagus were rare. These data partially confirm the reported low frequency of SMTs in the large intestine and esophagus,^{4,5,8} but differ with the reported frequency of SMTs in the stomach compared with the small intestine.^{4,5}

483 In the human literature, soft tissue SMTs are divided into two major groups: superficial and 484 deep-seated. However, deep-seated SMTs have not been previously identified in 485 veterinary medicine. Interestingly, in this study, half of the superficial cases were in the 486 perineal/perianal region, and half of the deep-seated cases were in the pelvic cavity or 487 within the tissues of the pelvic diaphragm. Thus, 10/21 cases (15/21 if the retroperitoneal 488 SMTs are included) arose in the soft tissues adjacent to the genital system. While the 489 retroperitoneal location of leiomyosarcoma has been occasionally reported in the dog,¹¹ 490 the occurrence of SMTs in the pelvic cavity and peri-genital soft tissue of dogs is novel and 491 parallels reports in human medicine.⁶ Human deep-seated leiomyomas arise most

492 frequently in the pelvic cavity and retroperitoneum, and are believed to arise from 493 hormonally-sensitive, resident smooth muscle cells.^{6,7,16} These tumors express the ER and 494 PR, and are referred to as leiomyoma of the gynecologic type.^{6,7,13} In our case series, 7 495 soft tissue SMTs expressed one or both hormone receptors and were all located in peri-496 genital soft tissues. There is a discrepancy between our findings and the human literature, 497 since 6/7 of the peri-genital SMT cases in this study were diagnosed as leiomyosarcoma, 498 not leiomyoma, by both the veterinary and human criteria. However, if we classified the 499 peri-genital soft tissue SMTs using the human genital SMT criteria,¹³ only 2 cases were 500 diagnosed as canine leiomyosarcoma, and one of these had distant metastases. The 501 application of the human criteria used for genital SMTs to extra-genital, hormone receptor-502 positive cases seems reasonable, but, as for genital SMTs, prospective studies are 503 recommended to justify and validate these diagnostic criteria. 504 In this study, the veterinary and human criteria led to the same diagnoses for urinary 505 bladder and splenic SMTs. The majority of SMTs in the urinary bladder were diagnosed as 506 leiomyosarcoma with both the veterinary and human criteria. This result contrasts with 507 previous data that report benign SMTs of the urinary bladder to be more frequent.²

508 Nevertheless, the lack of prognostic studies on SMTs in this location makes hypotheses509 on this matter speculative.

510 In the cases for which follow-up data were available, proliferative activity and tumor cell 511 necrosis strongly correlated with metastasis and tumor-related death. Tumor cell necrosis 512 also correlated with decreased differentiation and lack of desmin expression. Even though 513 these parameters were part of the diagnostic algorithm, the diagnosis of leiomyoma or 514 leiomyosarcoma, based on the veterinary or human criteria, did not correlate with clinical 515 variables. This may be a consequence of the small number of events available in this case 516 series. Therefore, further prognostic studies are necessary to confirm the prognostic value 517 of those parameters. Prediction of local recurrence is also a topic for future studies and

should include assessment of the status of surgical margins and infiltrative growth. In the present case series, only two cases of recurrence were recorded. Of these, only one had a known status of the surgical margins. Furthermore, only one of the cases in this study had clear evidence of infiltrative growth, which is included in the veterinary criteria. These limitations are likely the consequence of the retrospective nature of this study, and conclusions on this matter cannot be drawn based on the present data.

525 of leiomyosarcoma independent of the criteria used: soft tissue location; male sex; Ki67 526 labeling index; reduced differentiation; and mixed collagen pattern. These parameters may 527 provide further support to the diagnosis of malignancy, and therefore warrant further 528 consideration as to whether they should be added to the current diagnostic criteria. The 529 veterinary criteria currently include, tissue infiltration, mitotic count and tumor cell necrosis. 530 The human criteria include nuclear atypia, in addition to mitotic count and tumor cell 531 necrosis. Intact female sex was associated with malignancy when we applied the 532 veterinary criteria, while it was associated with leiomyoma and SMT-UMP when we used 533 the human criteria. This discrepancy is likely a consequence of the reclassification of many 534 of the SMTs located in the female genital tract using the human criteria. 535 Further variables associated with the diagnosis of leiomyoma and SMT-UMP when 536 applying the human criteria included: female genital tract; presence of slender nuclei; 537 nuclear palisading; myxoid change, and trabecular pattern. These data suggest that these 538 features, although uncommon, may be particular to SMTs of genital origin. 539 In conclusion, this study describes and compares the clinicopathological features of canine 540 SMTs in different organ systems and describes for the first time soft tissue SMTs of 541 gynecologic type in dogs. Our results also expand the knowledge of SMTs of soft tissues, 542 by describing deep-seated SMTs, their preferential peri-genital location, and the ER and/or 543 PR expression in a subset of these tumors. These data suggest the usefulness of the

544	human criteria to differentiate benign from malignant SMTs of the female genital tract in
545	dogs because the human criteria better predicted the biological behavior of the tumors. ²
546	Furthermore, the application of guidelines from the human criteria to assess nuclear atypia
547	and tumor cell necrosis ² seem to help prevent overdiagnosis of malignant SMTs. Further
548	prognostic studies are warranted to confirm the better performance of the human criteria in
549	genital SMTs, where the diagnosis of malignancy seems to be overestimated by the
550	veterinary criteria and where a benign behavior is generally expected. Further work is also
551	needed to assess the usefulness of the human criteria in hormone receptor-expressing
552	SMTs of soft tissue in dogs and to define the prognostic parameters for canine SMTs in
553	general.
554	
555	Acknowledgments
556	We thank Leah Cannon, PhD, for editing a draft of this manuscript.
557	
558	Declaration of conflicting interests
559	The author(s) declared no potential conflicts of interest with respect to the research,
560	authorship, and/or publication of this article.
561	
562	Funding
563	The author(s) received no financial support for the research, authorship, and/or publication
564	of this article.
565	
566	

567 References

- Buuren S van, Groothuis-Oudshoorn K. mice : Multivariate Imputation by Chained
 Equations in R. *J Stat Softw.* 2011;45.
- Cooper BJ, Valentine BA. Tumors of muscle. In: Meuten DJ, ed. *Tumors in domestic animals*. Ames: Wiley-Blackwell; 2017:499–601.
- 572 3. Dennis MM, McSporran KD, Bacon NJ, Schulman FY, Foster RA, Powers BE.
- 573 Prognostic Factors for Cutaneous and Subcutaneous Soft Tissue Sarcomas in

574 Dogs. Vet Pathol. 2011;48:73–84.

- 575 4. Frost D, Lasota J, Miettinen M. Gastrointestinal Stromal Tumors and Leiomyomas in
- 576 the Dog: A Histopathologic, Immunohistochemical, and Molecular Genetic Study of
- 577 50 Cases. *Vet Pathol*. 2003;40:42–54.
- 578 5. Gillespie V, Baer K, Farrelly J, Craft D, Luong R. Canine Gastrointestinal Stromal
- 579 Tumors: Immunohistochemical Expression of CD34 and Examination of Prognostic
- 580 Indicators Including Proliferation Markers Ki67 and AgNOR. Vet Pathol.
- 581 **2011;48:283–291**.
- 6. Goldblum JR, Folpe AL, Weiss SW. Benign tumors of smooth muscle. In: Goldblum
- 583 JR, Folpe AL, Weiss SW, eds. *Enzinger & Weiss's soft tissue tumors*. Philadelphia,
- 584 PA: Elsevier; 2020:564–590.
- 585 7. Goldblum JR, Folpe AL, Weiss SW. Leiomyosarcoma. In: Goldblum JR, Folpe AL,
- 586 Weiss SW, eds. *Enzinger & Weiss's soft tissue tumors*. Philadelphia, PA: Elsevier;
 587 2020:591–613.
- 588 8. Hayes S, Yuzbasiyan-Gurkan V, Gregory-Bryson E, Kiupel M. Classification of
- 589 Canine Nonangiogenic, Nonlymphogenic, Gastrointestinal Sarcomas Based on
- 590 Microscopic, Immunohistochemical, and Molecular Characteristics. *Vet Pathol.*
- 5912013;50:779–788.
- 592 9. Linden D, Liptak JM, Vinayak A, et al. Outcomes and prognostic variables

- 593 associated with primary abdominal visceral soft tissue sarcomas in dogs: A
- 594 Veterinary Society of Surgical Oncology retrospective study. *Vet Comp Oncol.*

595 2019;17:265–270.

- Linder KE. Tumors of the spleen. In: Meuten DJ, ed. *Tumors in domestic animals*.
 Ames: Wiley-Blackwell; 2017:307–321.
- 598 11. Liptak JM, Dernell WS, Ehrhart EJ, Rizzo SA, Rooney MB, Withrow SJ.
- 599 Retroperitoneal sarcomas in dogs: 14 cases (1992-2002). *J Am Vet Med Assoc*.
 600 2004;224:1471–1477.
- Liu SM, Mikaelian I. Cutaneous smooth muscle tumors in the dog and cat. *Vet Pathol.* 2003;40:685–692.
- Miettinen M, Fetsch JFJ. Evaluation of biological potential of smooth muscle
 tumours. *Histopathology*. 2006;48:97–105.
- Millán Y, Gordon A, de los Monteros AE, Reymundo C, de las Mulas JM. Steroid
 receptors in canine and human female genital tract tumours with smooth muscle
 differentiation. *J Comp Pathol.* 2007;136:197–201.
- 15. Miyajima K, Oda Y, Oshiro Y, et al. Clinicopathological prognostic factors in soft
- tissue leiomyosarcoma: a multivariate analysis. *Histopathology*. 2002;40:353–359.
- 610 16. Paal E, Miettinen M. Retroperitoneal Leiomyomas. *Am J Surg Pathol*.
- 611 **2001;25:1355–1363**.
- 17. Pellegrino V, Muscatello L V, Sarli G, Avallone G. Canine Gastrointestinal Spindle
- 613 Cell Tumors Efficiently Diagnosed by Tissue Microarray-Based
- 614 Immunohistochemistry. *Vet Pathol*. 2018;55:678–681.
- 15 18. Roccabianca P, Schulman FY, Avallone G, et al. *Tumors of Soft Tissue. Surgical*
- 616 Pathology of Tumors of Domestic Animals. Vol 3. Kiupel M, ed. Chicago: CL Davis
- 617 Foundation; 2020.
- 19. Toledo G, Oliva E. Smooth muscle tumors of the uterus: a practical approach. *Arch*

619 *Pathol Lab Med*. 2008;132:595–605.

620

621 Figure legends

Figure 1. Age distribution of dogs with smooth muscle tumors (SMTs). Comparison of all
cases (red line) with the genital, alimentary, and soft tissue SMT groups. The x-axis

represents age (years), the y-axis represents the number of cases.

Figure 2. Organ system distribution of 103 canine smooth muscle tumors (SMTs). The

626 "miscellaneous" group comprising a primary renal and a gall bladder SMT are not

627 included. retroper.: retroperitoneum; int.: intestine

Figures 3-14. Smooth muscle tumors (SMTs), dog. Hematoxylin and eosin. **Figure 3.**

629 Leiomyoma, vagina. Well-differentiated neoplasm lacking atypia or mitotic activity. Figure

630 **4.** Leiomyosarcoma, soft tissue (perineum). Poorly differentiated, highly cellular neoplasm

631 with high mitotic activity. **Figure 5.** SMT of unknown malignant potential (UMP), vagina.

632 Well-differentiated neoplasm lacking nuclear atypia but with occasional mitoses. Figure 6.

633 Leiomyosarcoma, colon. Tumor cell necrosis with a typical scalloped profile and sparing of

634 perivascular neoplastic areas. **Figure 7.** Leiomyoma, uterus. Infarct-type necrosis

635 surrounded by angiogenesis at the interface with viable neoplastic tissue. **Figure 8.**

636 Leiomyoma, uterus. Sharp demarcation of infarct-type necrosis and hyalinized stroma at

637 the transition with viable cells. **Figure 9.** Leiomyosarcoma, urinary bladder. Prominent

638 nuclear atypia. **Figure 10.** Leiomyosarcoma, soft tissue (pelvic cavity). Multinucleated

639 neoplastic smooth muscle cells. **Figure 11.** Leiomyoma, urinary bladder. Hyperchromatic

nuclei and ancient change (intranuclear cytoplasmic inclusions). Figure 12. Leiomyoma,

vagina. Focal area of nuclear palisading. **Figure 13.** Leiomyoma, vagina. Trabecular

642 growth pattern. **Figure 14.** Leiomyoma, stomach. Focal mineralization.

643 Figures 15-17. Smooth muscle tumors (SMTs), dog. Masson's trichrome. Figure 15.

644 Small amount of collagen (interfascicular pattern). Figure 16. Moderate amount of

collagen (mixed interfascicular and interstitial pattern). Figure 17. Abundant collagen
(interstitial pattern).

647 Figures 18-23. Smooth muscle tumors (SMTs), dog. Immunohistochemistry. Figure 18. 648 Leiomyoma, vagina. Diffuse and strong immunolabeling for α -SMA . Figure 19. 649 Leiomyosarcoma, intestine. Diffuse and strong immunolabeling for desmin. Figure 20. 650 Leiomyosarcoma, urinary bladder. Multifocal and moderate immunolabeling for desmin. 651 Figure 21. Leiomyosarcoma, urinary bladder. Absence of immunolabeling for desmin. 652 Figure 22. Leiomyosarcoma, retroperitoneal soft tissue. Diffuse nuclear immunolabeling 653 for estrogen receptor. Figure 23. Leiomyoma, retroperitoneal soft tissue. Multifocal nuclear 654 immunolabeling for progesterone receptor. 655 Figure 24-27. The correlation between histological differentiation of canine smooth muscle 656 tumors (SMTs) with desmin expression (Fig. 24), tumor size (Fig. 25), Ki67 labeling index 657 (Fig. 26), and mitotic count (Fig. 27). The box plots show median and quartiles, whiskers 658 show minimum and maximum, and dots show outliers. Figure 28. Box plot representing 659 canine SMT tumor size distribution in the three diagnostic categories. **Figure 29.** Box plot 660 representing Ki67 labeling index distribution for canine SMTs in the three diagnostic 661 categories.